JP2024513958A5 - - Google Patents

Info

Publication number
JP2024513958A5
JP2024513958A5 JP2023562568A JP2023562568A JP2024513958A5 JP 2024513958 A5 JP2024513958 A5 JP 2024513958A5 JP 2023562568 A JP2023562568 A JP 2023562568A JP 2023562568 A JP2023562568 A JP 2023562568A JP 2024513958 A5 JP2024513958 A5 JP 2024513958A5
Authority
JP
Japan
Prior art keywords
cells
natural killer
population
combination
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023691 external-priority patent/WO2022216837A1/en
Publication of JP2024513958A publication Critical patent/JP2024513958A/ja
Publication of JP2024513958A5 publication Critical patent/JP2024513958A5/ja
Pending legal-status Critical Current

Links

JP2023562568A 2021-04-08 2022-04-06 Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療 Pending JP2024513958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172423P 2021-04-08 2021-04-08
US63/172,423 2021-04-08
US202163290361P 2021-12-16 2021-12-16
US63/290,361 2021-12-16
PCT/US2022/023691 WO2022216837A1 (en) 2021-04-08 2022-04-06 Treatment of cancer with nk cells and an egfr targeted antibody

Publications (2)

Publication Number Publication Date
JP2024513958A JP2024513958A (ja) 2024-03-27
JP2024513958A5 true JP2024513958A5 (cg-RX-API-DMAC10.html) 2025-04-14

Family

ID=83546563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562568A Pending JP2024513958A (ja) 2021-04-08 2022-04-06 Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療

Country Status (7)

Country Link
US (1) US20240366664A1 (cg-RX-API-DMAC10.html)
EP (1) EP4319772A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513958A (cg-RX-API-DMAC10.html)
KR (1) KR20240024049A (cg-RX-API-DMAC10.html)
CN (1) CN118103048A (cg-RX-API-DMAC10.html)
AU (1) AU2022253889A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022216837A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
KR20240131924A (ko) * 2023-02-24 2024-09-02 주식회사 엔케이맥스 항-EGFR 항체의약품과 병용하는 자연살해세포의 TKIs 내성 비소세포폐암 치료방법
JP2026511162A (ja) * 2023-03-24 2026-04-10 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 強化された抗腫瘍記憶応答を備える操作されたナチュラルキラー細胞
WO2025191139A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
MX2016002970A (es) 2013-09-06 2016-10-07 Aurigene Discovery Tech Ltd Compuestos peptidomimeticos ciclicos como inmunomoduladores.
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3613433B1 (en) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Anti-epidermal growth factor receptor (egfr) antibodies
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
CN105820248A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
WO2016142894A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
EP3400248A4 (en) 2016-01-10 2019-09-04 Sorrento Therapeutics, Inc. IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882833B2 (en) 2016-05-23 2021-01-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018026971A1 (en) 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
WO2019008154A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3- (AZOLYLMETHOXY) BIPHENYL DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
WO2019008152A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3-CYANOTHIOPHENE DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3697500A1 (en) 2017-10-18 2020-08-26 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
WO2019179390A1 (en) 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/egfr antibody molecules
CN112839666A (zh) 2018-05-14 2021-05-25 因达普塔治疗公司 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법

Similar Documents

Publication Publication Date Title
Shimasaki et al. NK cells for cancer immunotherapy
JP2024513522A5 (cg-RX-API-DMAC10.html)
Pistoia et al. Human γδ T-cells: from surface receptors to the therapy of high-risk leukemias
Rossi et al. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
JP2024513514A5 (cg-RX-API-DMAC10.html)
Vuckovic et al. Bone marrow transplantation generates T cell–dependent control of myeloma in mice
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
Sato et al. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes
JP2024515169A5 (cg-RX-API-DMAC10.html)
Van Ostaijen-Ten Dam et al. Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential
JP2007527245A (ja) レギュラトリーｔ細胞並びに免疫療法及び自己免疫応答の抑制におけるそれらの使用
KR20140092298A (ko) 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
Giang et al. Nanoparticles engineered as artificial antigen-presenting cells induce human CD4+ and CD8+ Tregs that are functional in humanized mice
JPH09510456A (ja) 同種リンパ球による癌の免疫療法
KR20220031541A (ko) 항-bcma car t 세포의 제조
CN115137752A (zh) 用于干细胞移植的方法
Nakasone et al. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
JP2024542159A5 (cg-RX-API-DMAC10.html)
PT2613801T (pt) Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma
Plaugher et al. Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer
Parisi et al. The more, the better:“do the right thing” for natural killer immunotherapy in acute myeloid leukemia
TW202328436A (zh) 具有減弱之TGF-β受體傳訊的工程化T細胞
JP2021516666A (ja) 前立腺がん特異的髄浸潤リンパ球およびその使用
AU2023257377A1 (en) Allogeneic t cells for treatment of hematological malignancies
Gonzalez-Brito et al. The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies